fasudil has been researched along with Autoimmune Diabetes in 5 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with fasudil or captopril suppressed not only the inflammation reaction but also the accumulation of the extracellular matrix due to the downregulation of TGF-β1 and MMP-9/TIMP-1, which induces the amelioration of the liver fibrosis with diabetes." | 1.48 | Fasudil alleviates hepatic fibrosis in type 1 diabetic rats: involvement of the inflammation and RhoA/ROCK pathway. ( Chu, L; Huo, M; Ma, ZH; Song, T; Wang, N; Xie, Y; Zhang, JP; Zhang, Y; Zhang, YY, 2018) |
| "The treatment with fasudil after the development of diabetes improved the metabolic abnormalities in OLETF rats, but could not suppress the progression of nephropathy." | 1.34 | A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. ( Higashi, K; Hyodo, N; Imakiire, T; Kikuchi, Y; Kushiyama, T; Miura, S; Oda, T; Suzuki, S; Yamada, M; Yamamoto, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, Y | 1 |
| Song, T | 1 |
| Huo, M | 1 |
| Zhang, Y | 1 |
| Zhang, YY | 1 |
| Ma, ZH | 1 |
| Wang, N | 1 |
| Zhang, JP | 1 |
| Chu, L | 1 |
| Waddingham, MT | 1 |
| Edgley, AJ | 1 |
| Astolfo, A | 1 |
| Inagaki, T | 1 |
| Fujii, Y | 1 |
| Du, CK | 1 |
| Zhan, DY | 1 |
| Tsuchimochi, H | 1 |
| Yagi, N | 1 |
| Kelly, DJ | 1 |
| Shirai, M | 1 |
| Pearson, JT | 1 |
| Nuno, DW | 1 |
| Lamping, KG | 1 |
| Biswas, PS | 1 |
| Gupta, S | 1 |
| Chang, E | 1 |
| Bhagat, G | 1 |
| Pernis, AB | 1 |
| Kikuchi, Y | 1 |
| Yamada, M | 1 |
| Imakiire, T | 1 |
| Kushiyama, T | 1 |
| Higashi, K | 1 |
| Hyodo, N | 1 |
| Yamamoto, K | 1 |
| Oda, T | 1 |
| Suzuki, S | 1 |
| Miura, S | 1 |
5 other studies available for fasudil and Autoimmune Diabetes
| Article | Year |
|---|---|
Fasudil alleviates hepatic fibrosis in type 1 diabetic rats: involvement of the inflammation and RhoA/ROCK pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus, Experimental; Diabetes Me | 2018 |
Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Diabetes Mellitus, Experimental; Dia | 2015 |
The role of rho kinase in sex-dependent vascular dysfunction in type 1 diabetes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus, Experimental; Diabetes Me | 2010 |
Aberrant ROCK activation promotes the development of type I diabetes in NOD mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; CD4-Positive T-Lymphocytes; Diabetes Mellitu | 2011 |
A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Carrier Proteins; Diabetes Me | 2007 |